Transforming cancer treatment and advancing new therapies through empowered science

Webcast ImageWebcast
3rd Quarter 2014 Financial Results (Live)
10/30/14 at 1:30 p.m. PT
3rd Quarter 2014 Financial Results
Thursday, October 30, 2014 1:30 p.m. PT  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Corporate Profile

Seattle Genetics is a biotechnology company focused on developing and commercializing innovative, empowered antibody-based therapies for the treatment of cancer. We are the industry leader in antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells.

The company’s lead product, ADCETRIS® (brentuximab vedotin) is an ADC that, in collaboration with Takeda Pharmaceutical Company Limited is commercially available for two indications in more than 45 countries, including the U.S., Canada, Japan and members of the European Union. Additionally, ADCETRIS is being evaluated broadly in more than 30 ongoing clinical trials. Seattle Genetics is also advancing a robust pipeline of clinical-stage ADC programs designed to address the unmet medical needs of people with cancer, including SGN-CD19A, SGN-CD33A, SGN-LIV1A, SGN-CD70A, ASG-22ME and ASG-15ME. Seattle Genetics’ ADC technology is employed by a number of leading biotechnology and pharmaceutical companies, including AbbVie, Agensys (an affiliate of Astellas), Bayer, Genentech, GlaxoSmithKline and Pfizer. Across both internal and collaborator programs, there are more than 20 ADCs in clinical development using our proprietary approach to empowering antibodies.

Download Documentation  Corporate Fact Sheet
Download Documentation  2013 Annual Report
Download Documentation  2014 Proxy Statement
Investor Contact
Peggy Pinkston
Senior Director, Corporate Communications
PHONE: (425) 527-4160
FAX: (425) 527-4001

Media Contact
Tricia Larson
Director, Public Relations
PHONE: 425-527-4180
Stock Quote
SGEN (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Change (%) Stock is Down 0.48 (1.36%)
Data as of 10/22/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >
10/14/14Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter 2014 Financial Results on October 30, 2014
BOTHELL, Wash.--(BUSINESS WIRE)--Oct. 14, 2014-- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it will report its third quarter 2014 financial results on Thursday, October 30, 2014 after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: LIVE access... 
Printer Friendly Version
09/29/14Seattle Genetics and Takeda Announce Positive Data from Phase 3 AETHERA Clinical Trial of ADCETRIS® (Brentuximab Vedotin) for Consolidation in Post-Transplant Hodgkin Lymphoma
Randomized Phase 3 Clinical Trial with ADCETRIS Demonstrates Statistically Significant Improvement in Progression-Free Survival Abstract Submitted to ASH for Presentation at the 2014 Annual Meeting; Regulatory Submissions Anticipated in 2015 Seattle Genetics to Host Conference Call and Webcast Today at 8:30 a.m. ET BOTHELL, Wash. & OSAKA, Japan--(BUSINESS WIRE)--Sep. 29, 2014-- Seattle Genetics, Inc. (Nasdaq: SGEN) a... 
Printer Friendly Version
09/26/14Seattle Genetics to Host Conference Call and Webcast on September 29, 2014 Regarding Top-line Data from ADCETRIS® (brentuximab vedotin) Phase 3 AETHERA Clinical Trial
BOTHELL, Wash.--(BUSINESS WIRE)--Sep. 26, 2014-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that its management will host a conference call and webcast on Monday, September 29, 2014, at 5:30 a.m. Pacific Time (PT) / 8:30 a.m. Eastern Time (ET) regarding top-line results from its ADCETRIS phase 3 AETHERA clinical trial for Hodgkin lymphoma patients at risk of relapse following autologous stem cell transplant. The live event will b... 
Printer Friendly Version
09/24/14Seattle Genetics Highlights Updated Progression-Free Survival and Overall Survival Data from ADCETRIS® (Brentuximab Vedotin) Frontline PTCL Phase 1 Clinical Trial at the ESMO 2014 Congress
ADCETRIS in Combination with CHP Chemotherapy Regimen Demonstrates Two-Year Overall Survival Rate of 80 Percent; Estimated Median Progression-Free Survival Not Yet Reached BOTHELL, Wash.--(BUSINESS WIRE)--Sep. 24, 2014-- Seattle Genetics, Inc. (Nasdaq:SGEN) today highlighted ADCETRIS (brentuximab vedotin) data to be presented at the 2014 European Society for Medical Oncology (ESMO) Congress being held September 26-30, 2014 in Madrid, ... 
Printer Friendly Version
09/10/14Seattle Genetics and Genmab Enter Into New Antibody-Drug Conjugate Collaboration
Additional collaboration combines Genmab’s proprietary antibodies and Seattle Genetics’ ADC technology New ADC program will target AXL expressed on multiple tumor types BOTHELL, Wash. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Sep. 10, 2014-- Seattle Genetics, Inc. (Nasdaq: SGEN) and Genmab A/S (OMX: GEN) today announced that the companies have entered into an additional antibody-drug conjugate (ADC) collaboration.... 
Printer Friendly Version
Quotes delayed at least 15 minutes. Market data provided by Interactive Data.

Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.